Introduction

In the pharmaceutical industry, compliance with regulatory requirements is non-negotiable. One of the cornerstones of maintaining compliance while ensuring product quality is effective batch reporting. However, traditional batch reporting can be time-consuming and labour-intensive, particularly when every detail must be reviewed manually. This is where the concept of Review by Exception (RBE) transforms the process, enabling pharmaceutical manufacturers to focus only on deviations and anomalies rather than analysing every data point.

In this blog, we’ll explore the fundamentals of batch reporting and RBE, their benefits in the pharma industry, and how Réalta Technologies supports this approach using cutting-edge technologies and tools.

What Are Batch Reports in Pharma?

Batch reports are comprehensive documents detailing every stage of a pharmaceutical manufacturing process, from raw material procurement to final product release. These reports serve as critical records for ensuring that each batch of a product complies with stringent regulatory standards, including FDA 21 CFR Part 11 and EU GMP Annex 11.

Batch reports typically include:

• Process parameters: Information on temperature, pressure, mixing speed, etc.
• Material traceability: Lot numbers and sources of raw materials.
• Quality control data: Test results to verify product integrity.
• Deviations and corrective actions: Any process anomalies and steps taken to address them.

While essential for compliance, manually reviewing batch reports is resource-intensive and can delay product release.

What Is Review by Exception (RBE)?

Review by Exception (RBE) is a modern approach to batch reporting that focuses on identifying and analysing deviations or anomalies rather than manually reviewing all data. With this method, only data points or events outside predefined parameters (exceptions) are flagged for review.

How It Works:

1. Parameter Definition: Acceptable ranges for critical process parameters (CPPs) and key quality attributes (KQAs) are predefined.
2. Data Monitoring: Advanced systems continuously monitor real-time and historical data.
3. Exception Alerts: Only deviations outside acceptable ranges are flagged for review.

RBE eliminates unnecessary reviews of compliant data, streamlining the batch release process while maintaining quality and regulatory adherence.

Benefits of Batch Reports with Review by Exception

1. Reduced Review Time

RBE drastically reduces the time required for batch reviews by highlighting only the exceptions, enabling faster product release without compromising quality.

2. Improved Resource Efficiency

By automating the identification of exceptions, RBE allows quality teams to focus their efforts on addressing critical issues, reducing manual workloads.

3. Enhanced Compliance

Automated monitoring and reporting ensure that every deviation is documented and addressed, meeting stringent regulatory requirements.

4. Improved Decision-Making

Dashboards and advanced analytics provide clear insights into trends and recurring exceptions, empowering manufacturers to implement preventive measures.

5. Cost Savings

Streamlined review processes lead to operational efficiencies, reducing costs associated with lengthy manual reviews and production delays.

6. Increase the accuracy of Exception Detection

When a review is performed manually on large quantities of data, the likelihood of missing a deviation is much larger than when with an automated review.

How Réalta Technologies Supports Batch Reporting and RBE

Réalta Technologies is at the forefront of providing pharmaceutical manufacturers with tailored solutions for batch reporting and Review by Exception. By combining industry expertise with advanced technology, we help clients implement efficient, compliant, and scalable systems for managing batch data.

Technologies and Tools We Use:

AVEVA PI System

1. 1. • Enables real-time data collection, storage, and visualisation for batch processes.
      • Provides seamless integration with other systems like MES and automation platforms.

1. 1. • Alerts stakeholders about deviations in real time, ensuring timely corrective actions.

PI Batch Interfaces

1. 1. • PI Interfaces for Batch Execution Systems allow PI to recreate the complex batch events in PI Event Frames from the rich information available in execution systems enabling customers to easily view their real-time process data within the context of their product and batch

PI Event Frames (EF Gen)

1. 1. • Automates the creation of complex batch events in PI Event Frames based on process conditions, allowing to properly frame the retrieval of critical process parameters, and enabling quick identification of exceptions

Syncade MES Integration

1. 1. • Facilitates integration with Manufacturing Execution Systems (MES) to streamline data flow and batch report generation.

RtReports

1. • RtReports is a fully configurable web-based enterprise reporting application used with the PI System for generating electronic and printed reports. RtReports can be used to produce repeatable reports through configuration and without programming

How Réalta Technologies Can Assist Your Facility

At Réalta Technologies, we specialise in designing and implementing robust solutions for batch reporting and Review by Exception in pharmaceutical manufacturing. Here’s how we can help:

1. Seamless Integration

We ensure seamless integration of batch reporting systems with your existing MES, automation, and data collection platforms. This unified approach ensures that all critical data is captured and analysed in real time.

2. Customisable Solutions

Every facility is unique, and so are its needs. Our team works closely with you to develop RBE parameters and customised dashboards that align with your operations and regulatory requirements.

3. Advanced Analytics

Using tools like SEEQ and PowerBI, we provide advanced analytics capabilities, enabling you to gain deeper insights into exceptions and optimise your processes accordingly.

4. Scalability

As your operations grow, our solutions can scale with you. Whether you’re adding new lines or increasing production capacity, Réalta Technologies ensures your systems remain robust and efficient.

5. Regulatory Expertise

With a deep understanding of pharmaceutical regulations, our team ensures that all batch reporting systems meet compliance requirements, including FDA 21 CFR Part 11 and EU GMP standards.

Conclusion

Batch reporting and Review by Exception are revolutionising the pharmaceutical industry, offering faster, more efficient, and compliant ways to manage batch data. With Réalta Technologies’ expertise and cutting-edge solutions, you can streamline your reporting processes, reduce costs, and ensure compliance with industry regulations.

Contact us today to learn how Réalta Technologies can help your pharmaceutical facility adopt Review by Exception and achieve operational excellence.

Phone: +353 21 243 9113

Email: sales@Realtatechnologies.com